Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke
Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke
The purpose of this study is to evaluate the safety and efficacy of autologous peripheral
 hematopoietic stem cell transplantation in ischemic stroke.
Stroke is among the main causes of mortality and disability of elderly population which still
 lack of efficient therapy. Stem sell transplantation provides a functional improvement after
 cerebral ischemia in rat models. Our study will recruit 40 ischemic stroke patients which
 will be divided into 2 groups (20 patients each): treatment group and control group. The
 former will be implanted with peripheral blood stem cell through anterior cerebral artery or
 middle cerebral artery (determined by the section of infarction) and receive convention
 stroke therapy. The latter only receive convention stroke therapy. The investigators expect
 that transplantation of the peripheral hematopoietic stem cell is safe and efficient to
 neurological recovery.
Inclusion Criteria:

 -  aged 40~70

 -  no consciousness disorders

 -  internal carotid artery territory infarction

 -  stroke happened < 1 year

 -  with stable hemiplegia, but remain dependent in daily life

 -  SSS(Scandinavian Stroke Scale) < 40

 Exclusion Criteria:

 -  pregnant women

 -  can't tolerate the test because of other disease, such as heart failure, liver
 failure, renal failure, abnormal blood coagulation, AIDS, combine other tumor or
 special condition